ABOUT US.

COVID-19 pandemic represents one of the deadliest and economically most consequential outbreaks in around 100 years. To date, only remdesivir (Gilead Sciences) has shown to possibly lower the time to recovery. In the past, developing antiviral agents has taken 5.9 years on average. In the current crisis, it appears feasible that this timeline will be significantly reduced if there were early signs of efficacy. Moreover, a candidate drug could be offered emergency use authorization by the U.S. Food and Drug Administration and similar designations by regulatory authorities across the world, as was the case with remdesivir.

Drug repurposing has been a successful strategy for a variety of therapeutic areas. In the case of COVID-19, compounds of interest include those that have previously been found to either be clinically efficacious or have in vitro activity against the coronaviruses that cause Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS), which share significant structural similarities with SARS-CoV-2, the virus that causes COVID-19. Information on drugs potentially active against COVID-19 is expected to change rapidly as future studies will report. It is crucial that both researchers and health care providers are able to access the optimum and most up-to-date information to inform future or ongoing studies and provide clinical care.

The objectives for the current protocol are: 


    (1) to systematically review which existing medications have shown to be potentially effective             against SARS or MERS and could therefore be potentially repurposed;
    (2) to present the early evidence that supports testing readily available drugs against SARS-             CoV-2;
    (3) to provide the best available level of evidence for the efficacy of each individual candidate           drug; and
    (4) to report harmful effects associated with use of these drugs.

OUR TEAM

Ben Geisler.JPG

Benjamin P. Geisler

Principal investigator

MD MPH FACP MRCP (London)

Haining Yu.JPG

Haining Yu

Reviewer

MD MPH, University of California San Francisco Medical Center,

Lara Zahabi-Bekdash

Lara Zahabi

Reviewer

MD, PhD, MHSc

Ljiljana Lukić

Reviewer

MD MSc PhD

University Hospital for Infectious Disease Zagreb

Knakita Clayton-Johnson

Reviewer

MD, Portmore Hospital Complex

Jay Ahn

Automation and Web Engineer

Ash Parasa

Automation and Web Engineer

074F2AC9-2CCF-45B8-8D81-29A125479C68 - A

Adam Edward Lang

Reviewer

PharmD, BCACP, US Army Medical Department (AMEDD)

Farrin Manian

Farrin A. Manian

Reviewer

MD MPH FACP FIDSA FSHEA, Massachusetts General Hospital/Harvard Medical School

Elaine Tennant

Reviewer

BMedSci, BMBS, MRCP-UK, DTMH, MPHTM, FRACP, Infectious Diseases Physician Sydney

Elad Sharon

Reviewer

Communication

MD, MPH

National Cancer Institute

AAljaberi_1SQUARE - Ahmed Aljabery.jpg

Ahmed Aljaberi

Reviewer

MD, Brigham and Women’s Hospital

Hai-Hua Chuang.jpg

Hai-Hua Chuang

Reviewer

MD, Linkou Chang Gung Memorial Hospital/Chang Gung University

Chang-Berm Kang

Reviewer

Website Coordinator

MBA

Proof Biotechnologies

Learn more

Debbie Lin Teodorescu

Automation Coordinator

MD, MEng, AM

Naomi Eastwood

Reviewer

MBBS, Wirral University Teaching Hospital NHS Foundation Trust

Dennis Sun

Lead, Automation and Web Engineering Core

Ph.D., Statistics, M.S., Electrical Engineering

Max Barshay

Automation and Web Engineer

Rupal Totale

Automation and Web Engineer

Shubham Sengar

Automation and Web Engineer

Ryuhei Shida

Automation and Web Engineer